56 results on '"Cripe L"'
Search Results
2. Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: PHASE 1 STUDY EVALUATING LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS
3. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
4. Ventricular Assist Device Outcomes in Children and Young Adults with Muscular Dystrophy: An ACTION Analysis
5. DMD & BMD – CLINICAL
6. O.28Safety and tolerability of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy: results from a phase 1 clinical trial
7. DMD CLINICAL
8. DMD BRAIN
9. EP.83Design of a Phase 2/3 randomized controlled trial of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy amenable to exon 51 skipping
10. DUCHENNE MUSCULAR DYSTROPHY - GENETICS
11. DUCHENNE MUSCULAR DYSTROPHY – CLINICAL
12. DUCHENNE MUSCULAR DYSTROPHY - GENETICS
13. DUCHENNE MUSCULAR DYSTROPHY – IMAGING AND BIOMARKERS
14. Adolescence with Duchenne and Becker muscular dystrophy: a cardiac magnetic resonance comparison study
15. The heart is a muscle too: the cardiomyopathy of Duchenne muscular dystrophy
16. Duchenne muscular dystrophy patients with chest pain require cardiac evaluation: A report of eight DMD patients presenting with chest pain, marked troponin elevation, and worsening cardiomyopathy
17. Effects of long-term treatment with eteplirsen on cardiac function
18. Cardiac evaluation in Duchenne muscular dystrophy patients presenting with acute severe chest pain
19. Evaluating the effect of a monetary incentive on performance of the 100-meter timed test in Duchenne muscular dystrophy
20. ECG abnormalities correlate with myocardial fibrosis by cardiac magnetic resonance imaging in DMD
21. Eteplirsen, a Phosphorodiamidate morpholino oligomer (PMO) for the treatment of Duchenne muscular dystrophy (DMD): Clinical update
22. Addressing discrepancies in care with the certified Duchenne care center program
23. Comparison of Right and Left Ventricular Systolic Function Indices in Duchenne Muscular Dystrophy: A Longitudinal Cardiac Magnetic Resonance Study
24. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia
25. T.P.1
26. P.2.17 Hypertrophic cardiomyopathy in a patient with Duchenne muscular dystrophy
27. Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome
28. P1.16 The heart in Duchenne muscular dystrophy: The Cincinnati experience
29. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia
30. Survival after nonmyeloablative versus myeloablative allotransplantation for AML/MDS.
31. P4.13 Growth hormone improves growth in Duchenne muscular dystrophy with steroid-induced growth failure
32. P4.09 Electrocardiographic abnormalities in Duchenne muscular dystrophy prior to the onset of cardiac dysfunction
33. P4.08 Prevalence of sinus tachycardia in Duchenne muscular dystrophy
34. Voreloxin single-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: Final results from a phase II study with three schedules.
35. Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia.
36. Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia
37. G.P.13.05 The diagnosis and management of Duchenne muscular dystrophy: Internationally generated care recommendations
38. Relationships among patient-level factors, religious coping, use of complementary and alternative medicine, and psychological outcomes in men with advanced cancer
39. Phase Ib/II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in relapsed or refractory AML patients
40. A phase II study of voreloxin as single agent therapy for elderly patients (pts) with newly diagnosed acute myeloid leukemia (AML)
41. Effect of coping styles on the psychological impact of discussing life expectancy for men with advanced cancer
42. Coping styles and psychological outcomes in men with advanced cancer
43. G.P.15.06 Identification of psychosocial needs of adolescent/young adults with Duchenne muscular dystrophy
44. G.P.1.06 Outcome of Duchenne muscular dystrophy patients treated with daily deflazacort, daily prednisone, low dose 10days on/10days off prednisone and high dose weekend prednisone
45. G.P.9.06 Impaired response to low-dose dobutamine stress in Duchenne muscular dystrophy
46. Integrated report of the phase 2 experience with XL999 administered IV to patients (pts) with NSCLC, renal cell CA (RCC), metastatic colorectal CA (CRC), recurrent ovarian CA, acute myelogenous leaukemia (AML), and multiple myeloma (MM)
47. P147 Management of haematological adverse events in MDS patients treated with lenalidomide
48. P148 Management of non-haematological adverse events in MDS patients treated with lenalidomide
49. Final report of a phase II study of oral cyclophosphamide, thalidomide, and prednisone (CTP) for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial: HEM01–21
50. Blade Consolidation of Multiple Atrial Septal Defects: A Novel Approach to Transcatheter Closure
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.